Form 4: Amgen EVP Murdo Gordon Reports Stock Disposition

Amgen Executive Vice President Murdo Gordon disposed of 615 shares of common stock to cover tax obligations.

Summary

• Murdo Gordon, EVP of Global Commercial Operations at Amgen, disposed of 615 shares of common stock.
• The transaction occurred on May 7, 2026, at a price of $331.11 per share.
• The disposition was executed via code 'F', indicating a withholding of shares to satisfy tax liability related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 51,222 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a market-driven divestment.

Positives

• The transaction is a routine administrative action related to tax withholding rather than a discretionary sale of shares.

Negatives

• Reduction in the total number of shares held directly by a key executive.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that routine tax-related share withholding by executives is a standard practice in the biopharmaceutical industry and does not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices observed at large-cap pharmaceutical companies like Pfizer, Merck, and Bristol Myers Squibb.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard tax-related equity settlement.

Next Steps

• None

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Equity Incentive Plan